Table 2 Summary of adverse events
From: Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV
Preferred terms | All events | Drug-associated likely |
|---|---|---|
Abnormal indicators | 62 (100%) | 6 (9.6%) |
Hyperlipidemia | 24 (38.7%) | 1 (1.6%) |
Syphilis | 1 (1.6%) | 0 |
Hypercholesterolemia | 8 (12.9%) | 1 (1.6%) |
Hypertension | 3 (4.8%) | 0 |
Uarthritis | 9 (14.5%) | 1 (1.6%) |
Diabetes | 9 (14.5%) | 0 |
Renal insufficiency | 6 (9.8%) | 1 (1.6%) |
Upper respiratory tract infection | 1 (1.6%) | 1 (1.6%) |
Sore throat | 1 (1.6%) | 1 (1.6%) |